Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 17/20 | 0.60 |
| ▸ | HSP90AB1 known ✓ | P08238 | 7/20 | 0.60 |
| ▸ | HDAC3 known ✓ | O15379 | 8/20 | 0.55 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 8/20 | 0.55 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 8/20 | 0.55 |
| ▸ | HDAC1 known ✓ | Q13547 | 7/20 | 0.55 |
| ▸ | HDAC4 known ✓ | P56524 | 4/20 | 0.54 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 4/20 | 0.54 |
| ▸ | HDAC2 known ✓ | Q92769 | 4/20 | 0.54 |
| ▸ | HDAC10 known ✓ | Q969S8 | 4/20 | 0.54 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 4/20 | 0.54 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 4/20 | 0.54 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 4/20 | 0.54 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.56 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384821 | 0.99 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL382696 | 0.94 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL12572449 | 0.89 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL12802840 | 0.88 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL384542 | 0.88 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL12572459 | 0.86 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL382495 | 0.86 | HSP90B1 (0.67) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL12572543 | 0.85 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL383259 | 0.85 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 | |
| SCHEMBL16168764 | 0.84 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1HSP90B1HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2015-02-12 | — | — | US | disclosed |
| US-8916552-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-12-23 | — | — | US | disclosed |
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| EP-2332909-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8816087-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| US-8779132-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8530469-B2 | Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-20100152184-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-7700625-B2 | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 | ASTEX THERAPEUTICS LTD. (GB) | 2010-04-20 | — | — | US | disclosed |
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090215772-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LIMITED (UK) | 2009-08-27 | — | — | US | disclosed |
| EP-2073807-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HDAC3 639/4885 |
| US-20100092474-A1 | PHARMACEUTICAL COMBINATIONS | HSP90AB1, HEATR6, HEATR1 | HSP90AA1 4/4885HSP90AB1 1/4885HDAC3 384/4885 |
| US-20100152184-A1 | PHARMACEUTICAL COMPOUNDS | RPP30, RPLP1, NR5A1 | HSP90AA1 7/4885HSP90AB1 4/4885HDAC3 270/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HDAC3 644/4885 |
| US-20090215772-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HDAC3 560/4885 |
| US-20150045362-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HDAC3 644/4885 |
| US-20090298818-A1 | PHARMACEUTICAL COMPOUNDS | H1-10, C1R, C1S | HSP90AA1 3726/4885HSP90AB1 4036/4885HDAC3 624/4885 |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, CDK6 | HSP90AA1 68/4885HSP90AB1 23/4885HDAC3 241/4885 |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HDAC3 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.